SGLT2i use linked to lower risk for neurodegenerative disease in T2DM
By
HealthDay News
Sep 18, 2024
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
Diabetes, prediabetes tied to accelerated brain aging
By
Haymarket Media
Sep 10, 2024
The association was strongest among men and people with poor cardiometabolic health.
SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.
COVID-19 continues to affect leading causes of death in US: CDC
By
Kimberly Bonvissuto
Aug 12, 2024
The COVID-19 pandemic radically altered the rankings of the leading causes of death in the United States in 2020, and although COVID ranks lower on the list of causes in 2023, its effects continue to be...
Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
New symptoms, conditions may develop after positive test for SARS-CoV-2
Feb 11, 2022
Among hospitalized patients aged 20 years or older, the prevalence of new fatigue and type 2 diabetes were up for those with a positive versus a negative SARS-CoV-2 result.
Model estimates mortality risk in adults with dementia
Oct 14, 2022
A mortality prediction may help guide treatment and advance care planning for community-dwelling older adults with dementia.
SARS-CoV-2 infection linked to increased risk for diabetes
Apr 18, 2023
The fraction of incident diabetes cases attributable to SARS-CoV-2 infection was 3.41% overall and 4.75% among men.
Diabetes medications may offset severity of Alzheimer’s
By
John O'Connor
Nov 05, 2018
People with Alzheimer’s disease who were treated with diabetes drugs showed considerably fewer symptoms, Mount Sinai researchers have found.